Cullinan Therapeutics, Inc.

Contributing Author

Recent Articles by Cullinan Therapeutics, Inc.

Oct-08	Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia CGEM GlobeNewswire
Oct-01	New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program CGEM -5.34% CGEM +6.74% GlobeNewswire
Sep-24	Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio CGEM -8.48% GlobeNewswire
Sep-21	Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum CGEM GlobeNewswire
Sep-14	Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer CGEM GlobeNewswire
Sep-10	Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer CGEM GlobeNewswire
Aug-06	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CGEM GlobeNewswire
Jul-28	Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML CGEM GlobeNewswire
Jun-10	Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases CGEM -8.57% GlobeNewswire
Jun-06	Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress CGEM GlobeNewswire
May-26	Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager CGEM +11.71% GlobeNewswire
May-19	Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia CGEM GlobeNewswire
May-18	Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress CGEM -5.47% GlobeNewswire
May-07	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results CGEM GlobeNewswire
Mar-10	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results CGEM GlobeNewswire
Feb-24	Cullinan Therapeutics to Participate in Upcoming Investor Conferences CGEM GlobeNewswire
Feb-18	Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit CGEM GlobeNewswire
Feb-05	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 CGEM GlobeNewswire
Jan-08	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones CGEM GlobeNewswire
Dec-08	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting CGEM +17.47% GlobeNewswire
Dec-01	Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia CGEM -5.45% GlobeNewswire
Nov-10	Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting CGEM GlobeNewswire
Nov-06	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results CGEM GlobeNewswire
Nov-03	Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting CGEM -9.82% GlobeNewswire
Oct-25	Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 CGEM GlobeNewswire
Sep-12	Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum CGEM GlobeNewswire
Aug-21	Cullinan Therapeutics to Participate in Upcoming Investor Conferences CGEM CGEM +6.78% GlobeNewswire
Aug-07	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CGEM -10.79% GlobeNewswire
Jun-04	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases CGEM GlobeNewswire
May-29	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference CGEM +10.71% GlobeNewswire
May-08	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results CGEM GlobeNewswire

Cullinan Therapeutics, Inc.

Recent Articles by Cullinan Therapeutics, Inc.

Upgrade your Finviz experience